The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7196-7203

  Rusnak, David W ^a   Mullin, Robert J ^a   Alligood, Krystal J ^a   Keith, Barry R ^a   Crosby, Renae M ^a   Murray, Doris M ^a   Gilmer, Tona M ^a   Wood, Edgar R ^a   Reep, Bryan R ^a   Knight, W Blaine ^a   Brignola, Perry S ^a   Kadwell, Sue H ^a   Lackey, Karen ^a   Affleck, Karen ^b   Harris, Robert ^b,e   Shaw, Robert J ^b   Cockerill, Stuart G ^b,c   Guntrip, Stephen B ^b   Smith, Kathryn J ^b   Carter, Malcolm C ^b   Stubberfield, Colin ^b,d   Page, Martin ^b,d   Stables, Jeremy ^b,c   Jowett, Amanda ^b   Topley, Peter ^b   more..

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Carlshalton   (United Kingdom)

^d Oxford Glycosciences Abindgdon Science Park   (United Kingdom)

^e OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GB 2345486; GW 0277; GW 2974; GW 4263; GW 5280146; GW 5289; GW 5945; GW 5949; GW 9263; GW 9525; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG USE; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; GROWTH INHIBITORS; HUMANS; MICE; MICE, SCID; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035476866     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. The ErbB signaling network: Receptor heterodimerization in development and cancer
2. Neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer
3. Evidence for a role of EGF receptor in the progression of human lung carcinoma
4. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations
5. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer
6. Evaluation of epidermal growth factor receptor, transforming growth factor α, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer
7. Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B2 expression in patients with breast cancer
8. Correlation between ploidy status, ERB-B2 and P53 immunohistochemical expression in primary breast carcinoma
9. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short term prognosis in breast cancer
10. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
11. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
12. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
13. HER-2/neu correlates with the stage of disease and survival in colorectal cancer
14. Amplification and expression of the c-erbB-2/neu proto-oncogene in human bladder cancer
15. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
16. c-erbB growth-factor-receptor proteins in ovarian tumours
17. Specificity within the EGF family/ErbB receptor family signaling network
18. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes
19. Akt/Protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation
20. Pharmacology and therapeutic use of trastuzumab in breast cancer
21. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
22. Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies
23. A Phase II trial of the epidermal growth factor receptor (EGFR) tryosine-kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
24. A Phase I, dose-escalation, pharmacokinetics (PK) and pharmacodynamic (PD) study of trial of ZD1839: NCIC CTG IND1.22
25. A Phase II, multicenter study of the epidermal growth factor receptor (EGFR) tryosine-kinase inhibitor (TK1), CP-358,774 in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN)
26. A Phase I, intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumors
27. Indzolylamino quinazolines and pyridopyrimidines as inhibitors of EGFr and c-erbB-2
28. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling
29. New model of erbB-2 over-expression in human mammary luminal epithelial cells
30. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
31. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5
32. Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: Measurement of c-erbB2 mRNA half-life
33. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin
34. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
35. Tyrosine kinase inhibitors, emodin and its derivative, repress Her-2/neu-induced cellular transformation and metastasis-associated properties
36. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors
37. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy
38. Tyrosine kinase inhibitors in cancer treatment (part II)
39. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
40. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
41. The EGF receptor: A nexus for trafficking and signaling
42. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor